CURx Pharmaceuticals

CURx Pharmaceuticals, Gilead Sciences form license agreement

Monday, February 24, 2014

CURx Pharmaceuticals, a San Diego-based developer of late-stage therapeutics with high medical need, has entered into a global license agreement with Gilead Sciences for development of Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. FTI is ready for phase III clinical trials, having successfully completed a phase II trial in CF patients.

[Read More]

Ligand, CURx enter global license agreement

Friday, August 16, 2013

Ligand Pharmaceuticals has entered a global license agreement with CURx Pharmaceuticals for the development and commercialization of Ligand’s Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate. Ligand will be eligible to receive more than $21 million in potential net milestone payments and net royalties on future sales of 6.0% to 7.5%.

[Read More]